Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, recently participated in the 2nd Annual Chardan Virtual Ophthalmology Conference Series. The company, which gained regulatory approval in the EU and UK for the first authorized ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD), was featured among 8 companies at the event. The conference focused on AMD and diabetes-related ocular diseases.
As part of the virtual event, Outlook Therapeutics' executives Russell Trenary (President and CEO) and Lawrence Kenyon (CFO) participated in a fireside chat hosted by Chardan's Senior Research Analyst, Daniil Gataulin, PhD. A video webcast of this discussion is now available for viewing online.
Outlook Therapeutics (Nasdaq: OTLK), una azienda biopharmaceutica, ha recentemente partecipato alla 2ª Conferenza Virtuale Annuale di Oftalmologia Chardan. L'azienda, che ha ottenuto l'approvazione normativa nell'UE e nel Regno Unito per la prima formulazione oftalmica autorizzata di bevacizumab per trattare la degenerazione maculare senile umida (wet AMD), è stata presentata insieme ad altre 7 aziende all'evento. La conferenza si è concentrata sulle malattie oculari correlate all'AMD e al diabete.
Come parte dell'evento virtuale, i dirigenti di Outlook Therapeutics Russell Trenary (Presidente e CEO) e Lawrence Kenyon (CFO) hanno partecipato a una chiacchierata informale ospitata dall'Analista Senior di Ricerca di Chardan, Daniil Gataulin, PhD. Una registrazione video di questa discussione è ora disponibile per la visione online.
Outlook Therapeutics (Nasdaq: OTLK), una empresa biofarmacéutica, participó recientemente en la 2ª Conferencia Virtual Anual de Oftalmología de Chardan. La empresa, que obtuvo la aprobación regulatoria en la UE y el Reino Unido para la primera formulación oftálmica autorizada de bevacizumab para tratar la degeneración macular relacionada con la edad húmeda (wet AMD), fue destacada entre 8 empresas en el evento. La conferencia se centró en la AMD y las enfermedades oculares relacionadas con la diabetes.
Como parte del evento virtual, los ejecutivos de Outlook Therapeutics Russell Trenary (Presidente y CEO) y Lawrence Kenyon (CFO) participaron en una charla informal moderada por el Analista Principal de Investigación de Chardan, Daniil Gataulin, PhD. Un video de esta discusión ya está disponible para ver en línea.
Outlook Therapeutics (Nasdaq: OTLK)는 최근 제2회 연례 차르단 가상 안과 회의에 참여했습니다. 이 회사는 습성 노인성 황반 변성을 치료하기 위한 최초의 승인된 안과용 베바시주맙 제형에 대해 EU와 영국에서 규제 승인을 받았습니다. 이 행사는 8개 회사 중 하나로 소개되었습니다. 회의는 AMD와 당뇨 관련 안구 질환에 초점을 맞췄습니다.
가상 이벤트의 일환으로 Outlook Therapeutics의 경영진인 러셀 트레너 (사장 및 CEO)와 로렌스 켄연 (CFO)이 차르단의 수석 연구 분석가인 다니일 가타울린 박사가 주최한 간담회에 참여하였습니다. 이 논의의 비디오 웹캐스트는 온라인에서 시청할 수 있습니다.
Outlook Therapeutics (Nasdaq: OTLK), une entreprise biopharmaceutique, a récemment participé à la 2e Conférence Virtuelle Annuelle d'Ophthalmologie Chardan. L'entreprise, qui a obtenu l'approbation réglementaire dans l'UE et au Royaume-Uni pour la première formulation ophtalmique autorisée de bevacizumab pour traiter la dégénérescence maculaire liée à l'âge humide (wet AMD), a été mise en avant parmi 8 entreprises lors de l'événement. La conférence s'est concentrée sur l'AMD et les maladies oculaires liées au diabète.
Dans le cadre de l'événement virtuel, les dirigeants d'Outlook Therapeutics, Russell Trenary (Président et CEO) et Lawrence Kenyon (CFO), ont participé à une discussion informelle animée par l'analyste senior de recherche de Chardan, Daniil Gataulin, PhD. Un webinaire vidéo de cette discussion est désormais disponible pour visionnage en ligne.
Outlook Therapeutics (Nasdaq: OTLK), ein biopharmazeutisches Unternehmen, hat kürzlich an der 2. jährlichen virtuellen Chardan-Konferenz für Augenheilkunde teilgenommen. Das Unternehmen, das in der EU und im Vereinigten Königreich die regulatorische Genehmigung für die erste genehmigte augenheilkundliche Formulierung von Bevacizumab zur Behandlung von feuchter altersbedingter Makuladegeneration (wet AMD) erhalten hat, wurde bei der Veranstaltung unter 8 Unternehmen hervorgehoben. Die Konferenz konzentrierte sich auf AMD und diabetesbedingte Augenkrankheiten.
Im Rahmen der virtuellen Veranstaltung nahmen die Führungskräfte von Outlook Therapeutics, Russell Trenary (Präsident und CEO) und Lawrence Kenyon (CFO), an einem Kamin-Gespräch teil, das von Daniil Gataulin, PhD, einem leitenden Forschungsanalysten bei Chardan, moderiert wurde. Eine Video-Webcast dieser Diskussion ist jetzt online verfügbar.
- Regulatory approval in EU and UK for ophthalmic formulation of bevacizumab to treat wet AMD
- Participation in a prominent ophthalmology conference
- Company executives featured in a fireside chat, potentially increasing visibility
- None.
Webcast replay of fireside chat now available
ISELIN, N.J., Sept. 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that the Company recently participated in the 2nd Annual Chardan Virtual Ophthalmology Conference Series.
Chardan’s 2nd Annual Virtual Ophthalmology Summit focused on age-related macular degeneration (AMD) and diabetes-related ocular diseases and featured 8 companies pursuing various differentiated approaches in treating serious eye conditions, including Outlook Therapeutics. As part of the virtual event, Russell Trenary, President and Chief Executive Officer and Lawrence Kenyon, Chief Executive Officer of Outlook Therapeutics participated in a fireside chat hosted by Daniil Gataulin, PhD, Senior Research Analyst at Chardan.
A video webcast of the fireside chat is now available here.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
What recent conference did Outlook Therapeutics (OTLK) participate in?
What regulatory approvals has Outlook Therapeutics (OTLK) received in 2024?
Who represented Outlook Therapeutics (OTLK) at the Chardan Virtual Ophthalmology Conference?
Is there a recording available of Outlook Therapeutics' (OTLK) presentation at the Chardan conference?
